| Dr Elizabeth A Weaver, MD | |
|
9825 Kenwood Rd, Suite 105, Blue Ash, OH 45242-6251 | |
| (513) 872-4500 | |
| (513) 872-4518 |
| Full Name | Dr Elizabeth A Weaver |
|---|---|
| Gender | Female |
| Speciality | Diagnostic Radiology |
| Experience | 27 Years |
| Location | 9825 Kenwood Rd, Blue Ash, Ohio |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053367276 | NPI | - | NPPES |
| 2498971 | Medicaid | OH | |
| 200487850 | Medicaid | IN | |
| 64087513 | Medicaid | KY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 35083588 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| The Jewish Hospital-mercy Health | Cincinnati, OH | Hospital |
| Marcum And Wallace Memorial Hospital | Irvine, KY | Hospital |
| Christ Hospital | Cincinnati, OH | Hospital |
| Mercy Health - West Hospital | Cincinnati, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Seven Hills Ob-gyn Associates Llc | 0749188142 | 109 |
| Professional Radiology Inc | 0941298764 | 38 |
| Professional Radiology Inc | 0941298764 | 38 |
News Archive
ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of brain and other cancers, announced today that it has filed a provisional patent application at US Patent Office seeking protection of intellectual property relating to novel glycosylated epitopes present in lung cancer, pancreatic cancer and colon cancer that are targeted by the Company's ICT-109 monoclonal antibody product candidate.
Hard to Treat Diseases (HTDS) http://www.htdsmedical.com the company has been asked to comment on recent activity in its stock price. First, we would like our shareholders to be reassured and take comfort in the fact that there is no news that they do not know about. While there are several significant pending transactions they are not ready to be announced yet, however will be in due and appropriate time.
In the first study of how weight may affect school attendance, researchers at the University of Pennsylvania and Temple University have found that overweight children are at greater risk of school absenteeism than their normal-weight peers.
FiReGlobal : West Coast is proud to announce that Hoana Medical, Inc. has been selected as a FiReStar company to be featured at the FiReGlobal : West Coast conference. FiReStar companies, both local and global, are pre-selected based on their potential to bring positive change to the world. These companies will be showcased throughout the conference, and at a FiReStar reception, during which local and global investors will be given the chance to meet company officers.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with paclitaxel (Taxol), a standard chemotherapy regimen, will be presented during the 33rd Annual San Antonio Breast Cancer Symposium (SABCS) being held December 8-12, 2010 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.
› Verified 1 days ago
| Entity Name | Seven Hills Ob-gyn Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609856525 PECOS PAC ID: 0749188142 Enrollment ID: O20040128000116 |
News Archive
ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of brain and other cancers, announced today that it has filed a provisional patent application at US Patent Office seeking protection of intellectual property relating to novel glycosylated epitopes present in lung cancer, pancreatic cancer and colon cancer that are targeted by the Company's ICT-109 monoclonal antibody product candidate.
Hard to Treat Diseases (HTDS) http://www.htdsmedical.com the company has been asked to comment on recent activity in its stock price. First, we would like our shareholders to be reassured and take comfort in the fact that there is no news that they do not know about. While there are several significant pending transactions they are not ready to be announced yet, however will be in due and appropriate time.
In the first study of how weight may affect school attendance, researchers at the University of Pennsylvania and Temple University have found that overweight children are at greater risk of school absenteeism than their normal-weight peers.
FiReGlobal : West Coast is proud to announce that Hoana Medical, Inc. has been selected as a FiReStar company to be featured at the FiReGlobal : West Coast conference. FiReStar companies, both local and global, are pre-selected based on their potential to bring positive change to the world. These companies will be showcased throughout the conference, and at a FiReStar reception, during which local and global investors will be given the chance to meet company officers.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with paclitaxel (Taxol), a standard chemotherapy regimen, will be presented during the 33rd Annual San Antonio Breast Cancer Symposium (SABCS) being held December 8-12, 2010 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.
› Verified 1 days ago
| Entity Name | Professional Radiology Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043348014 PECOS PAC ID: 0941298764 Enrollment ID: O20040503000207 |
News Archive
ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of brain and other cancers, announced today that it has filed a provisional patent application at US Patent Office seeking protection of intellectual property relating to novel glycosylated epitopes present in lung cancer, pancreatic cancer and colon cancer that are targeted by the Company's ICT-109 monoclonal antibody product candidate.
Hard to Treat Diseases (HTDS) http://www.htdsmedical.com the company has been asked to comment on recent activity in its stock price. First, we would like our shareholders to be reassured and take comfort in the fact that there is no news that they do not know about. While there are several significant pending transactions they are not ready to be announced yet, however will be in due and appropriate time.
In the first study of how weight may affect school attendance, researchers at the University of Pennsylvania and Temple University have found that overweight children are at greater risk of school absenteeism than their normal-weight peers.
FiReGlobal : West Coast is proud to announce that Hoana Medical, Inc. has been selected as a FiReStar company to be featured at the FiReGlobal : West Coast conference. FiReStar companies, both local and global, are pre-selected based on their potential to bring positive change to the world. These companies will be showcased throughout the conference, and at a FiReStar reception, during which local and global investors will be given the chance to meet company officers.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with paclitaxel (Taxol), a standard chemotherapy regimen, will be presented during the 33rd Annual San Antonio Breast Cancer Symposium (SABCS) being held December 8-12, 2010 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Elizabeth A Weaver, MD 9825 Kenwood Rd, Suite 105, Blue Ash, OH 45242-6251 Ph: (513) 872-4500 | Dr Elizabeth A Weaver, MD 9825 Kenwood Rd, Suite 105, Blue Ash, OH 45242-6251 Ph: (513) 872-4500 |
News Archive
ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of brain and other cancers, announced today that it has filed a provisional patent application at US Patent Office seeking protection of intellectual property relating to novel glycosylated epitopes present in lung cancer, pancreatic cancer and colon cancer that are targeted by the Company's ICT-109 monoclonal antibody product candidate.
Hard to Treat Diseases (HTDS) http://www.htdsmedical.com the company has been asked to comment on recent activity in its stock price. First, we would like our shareholders to be reassured and take comfort in the fact that there is no news that they do not know about. While there are several significant pending transactions they are not ready to be announced yet, however will be in due and appropriate time.
In the first study of how weight may affect school attendance, researchers at the University of Pennsylvania and Temple University have found that overweight children are at greater risk of school absenteeism than their normal-weight peers.
FiReGlobal : West Coast is proud to announce that Hoana Medical, Inc. has been selected as a FiReStar company to be featured at the FiReGlobal : West Coast conference. FiReStar companies, both local and global, are pre-selected based on their potential to bring positive change to the world. These companies will be showcased throughout the conference, and at a FiReStar reception, during which local and global investors will be given the chance to meet company officers.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with paclitaxel (Taxol), a standard chemotherapy regimen, will be presented during the 33rd Annual San Antonio Breast Cancer Symposium (SABCS) being held December 8-12, 2010 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.
› Verified 1 days ago
Eugene Paik, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 9825 Kenwood Rd, Suite 105, Blue Ash, OH 45242 Phone: 513-872-4500 Fax: 513-872-4518 | |
Dr. James R Cornwell, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 9825 Kenwood Rd, Suite 105, Blue Ash, OH 45242 Phone: 513-872-4500 Fax: 513-872-4518 | |
John Bora Tezel, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 9825 Kenwood Rd Ste 105, Blue Ash, OH 45242 Phone: 513-872-4500 | |
Matthew John Moore, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 9825 Kenwood Rd, Suite 105, Blue Ash, OH 45242 Phone: 513-872-4500 Fax: 513-872-4518 | |
Aditya Bahel, Radiology Medicare: Accepting Medicare Assignments Practice Location: 9825 Kenwood Rd, Blue Ash, OH 45242 Phone: 513-527-9999 | |
Dr. Joseph E Bernstein, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 9825 Kenwood Rd, Suite 105, Blue Ash, OH 45242 Phone: 513-872-4500 Fax: 513-872-4518 |